Core Viewpoint - Zhaoyan New Drug has announced a significant increase in its 2025 annual performance forecast, with a minimum increase of 945% in net profit excluding non-recurring items, despite a projected decrease in revenue [1][2]. Group 1: Financial Performance - The company expects to achieve an operating income of approximately 1.573 billion to 1.738 billion yuan in 2025, representing a decrease of about 13.9% to 22.1% compared to 2024 [2]. - The projected net profit for 2025 is estimated to be between 233 million to 349 million yuan, an increase of approximately 214% to 371% year-on-year [2]. - The net profit excluding non-recurring items is expected to be between 246 million to 370 million yuan, reflecting an increase of approximately 945.2% to 1467.7% compared to 2024 [2]. Group 2: Asset Valuation and Pricing - The increase in net profit is attributed to the positive change in the fair market value of biological assets, contributing approximately 452 million to 499 million yuan to net profit [2]. - The biological assets primarily consist of experimental models used for non-clinical research, with a significant price increase expected in the second half of 2025 [3]. - The average procurement price for non-human primate experimental animals reached a high of 150,000 to 200,000 yuan per unit in the second half of 2022, but declined to 70,000 to 100,000 yuan per unit by the second half of 2024 [3]. Group 3: Shareholder Actions - Following the strong performance of the stock, the actual controller of Zhaoyan New Drug, Zhou Zhiwen, has initiated a share reduction plan, having already sold over 10 million shares for more than 370 million yuan [1][4]. - As of January 26, 2026, the closing price of Zhaoyan New Drug was 41.39 yuan, with a market capitalization of approximately 31.02 billion yuan [4]. - Zhou Zhiwen plans to reduce his holdings by up to 14.98 million shares, which is about 1.99873% of the total share capital [4].

Summary of Conference Call on Monkey Price Trends Industry Overview - The conference call discusses the domestic monkey breeding industry, particularly focusing on the demand for experimental monkeys and the factors influencing their prices [1][2]. Key Points and Arguments Demand and Supply Dynamics - There is a strong demand for experimental monkeys from domestic DL companies, leading to a significant increase in orders, particularly from November and December 2023 [2]. - The supply of monkeys is constrained due to a shortage of animal resources, resulting in a market characterized by scattered orders rather than long-term contracts [3]. - The average price of experimental monkeys is expected to stabilize between 12-13 million yuan, with potential fluctuations up to 12-16 million yuan [4][13]. Quality and Quantity of Domestic Monkey Population - The overall population of monkeys remains stable, but the quality is declining, affecting both the output quantity and quality [5]. Importation of Monkeys - Cambodia began exporting experimental monkeys to China in December 2023, with Vietnam expected to follow in 2025 and Indonesia in 2026 [6]. - Imported monkeys are primarily for breeding purposes, but some meet experimental standards and can be sold as commercial monkeys [7]. Cost of Production - The cost of producing monkeys has increased due to additional testing requirements, raising the cost by approximately 700-800 yuan per monkey [8]. Future Supply Trends - A supply gap for commercial monkeys is anticipated to persist from 2026 to 2028, particularly severe in 2026 and 2027, with improvements expected by 2029 [9]. Impact of Overseas Demand - The price of experimental monkeys in the U.S. is significantly higher than in China, influencing domestic pricing strategies. For instance, when domestic prices are below 100,000 yuan, U.S. prices are around 140,000-150,000 yuan [10]. Revenue from Non-Standard Monkeys - The increase in output for 2025 is attributed to the sale of non-standard monkeys, which do not significantly boost revenue due to their lower price points [11]. Industry Pricing Levels - The current average market price for monkeys is between 110,000 and 120,000 yuan, with the company maintaining a competitive pricing strategy [12]. Challenges in Breeding Programs - Although breeding plans exist, the actual implementation is challenging due to the strong demand for immediate returns, making it difficult to retain breeding stock [16]. Influence of Domestic Innovation - The growth of domestic innovative pharmaceuticals is driving demand for monkeys, with usage surpassing that in the U.S. and a higher number of original drugs compared to Western countries [17]. Additional Important Insights - The market is shifting towards more flexible purchasing arrangements, with clients actively seeking monkeys rather than relying on long-term contracts [3]. - The potential for exporting monkeys is limited due to regulatory constraints, as they are considered a strategic resource [14]. - The cost of imported monkeys varies based on the gender ratio and country of origin, with Cambodian imports costing around 70,000-80,000 yuan per monkey [14]. This summary encapsulates the critical insights from the conference call regarding the monkey breeding industry, highlighting the interplay between demand, supply, pricing, and the impact of domestic and international factors.

Group 1 - The price of experimental monkeys has surged, with the cost for 3-5 year old crab-eating macaques reaching 140,000 yuan each as of December 9, indicating a supply-demand imbalance in the market [1] - The price of experimental monkeys had previously experienced significant fluctuations, peaking at nearly 200,000 yuan each around 2023 before dropping to as low as 50,000 yuan [1] - The current increase in monkey prices is linked to the upward cycle of innovative drugs and the recovery of orders in the CRO (Contract Research Organization) industry [1] Group 2 - Several CRO companies, including Zhaoyan New Drug and Yinos, have made significant investments in experimental monkeys, indicating a strategic focus on this resource [1] - Since 2018, leading companies such as WuXi AppTec and Kanglong Chemical have been acquiring monkey breeding facilities, reflecting a trend of stockpiling monkeys in anticipation of price increases [1] - A substantial rise in monkey prices could positively impact the fair value changes of companies' biological assets [1]